CN105492026B - 使用抗cgrp抗体的葡萄糖代谢的调节 - Google Patents

使用抗cgrp抗体的葡萄糖代谢的调节

Info

Publication number
CN105492026B
CN105492026B CN201480047723.5A CN201480047723A CN105492026B CN 105492026 B CN105492026 B CN 105492026B CN 201480047723 A CN201480047723 A CN 201480047723A CN 105492026 B CN105492026 B CN 105492026B
Authority
CN
China
Prior art keywords
seq
antibody
cgrp
sequences
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480047723.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN105492026A (zh
Inventor
J·A·莱瑟姆
J·T·L·史密斯
B·贝克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Alder Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS, Alder Biopharmaceuticals Inc filed Critical H Lundbeck AS
Publication of CN105492026A publication Critical patent/CN105492026A/zh
Application granted granted Critical
Publication of CN105492026B publication Critical patent/CN105492026B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Developing Agents For Electrophotography (AREA)
CN201480047723.5A 2013-07-03 2014-07-03 使用抗cgrp抗体的葡萄糖代谢的调节 Active CN105492026B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361842745P 2013-07-03 2013-07-03
US61/842,745 2013-07-03
US201461982611P 2014-04-22 2014-04-22
US61/982,611 2014-04-22
PCT/US2014/045389 WO2015003122A2 (en) 2013-07-03 2014-07-03 Regulation of glucose metabolism using anti-cgrp antibodies

Publications (2)

Publication Number Publication Date
CN105492026A CN105492026A (zh) 2016-04-13
CN105492026B true CN105492026B (zh) 2025-12-30

Family

ID=52144290

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480047723.5A Active CN105492026B (zh) 2013-07-03 2014-07-03 使用抗cgrp抗体的葡萄糖代谢的调节

Country Status (14)

Country Link
US (1) US20150017166A1 (https=)
EP (1) EP3016684B1 (https=)
JP (4) JP6502337B2 (https=)
KR (1) KR102476907B1 (https=)
CN (1) CN105492026B (https=)
AU (2) AU2014285052B2 (https=)
CA (1) CA2916980C (https=)
ES (1) ES2911690T3 (https=)
IL (1) IL243355B2 (https=)
MX (1) MX374612B (https=)
NZ (1) NZ754427A (https=)
SG (2) SG10201906172XA (https=)
TW (2) TWI712419B (https=)
WO (1) WO2015003122A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL243355B2 (en) * 2013-07-03 2024-10-01 Lundbeck Seattle Biopharmaceuticals Inc Regulation of glucose metabolism using anti-cgrp antibodies
AU2015230933B2 (en) 2014-03-21 2020-08-13 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
CN109952314A (zh) 2016-09-23 2019-06-28 泰瓦制药国际有限公司 治疗难治性偏头痛
CA3077973A1 (en) 2020-04-06 2021-10-06 H. Lundbeck A/S Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies
CN116057185A (zh) * 2020-08-15 2023-05-02 雷杰纳荣制药公司 治疗具有编码降钙素受体(calcr)的变体核酸分子的受试者的肥胖症
IL310885A (en) 2021-08-27 2024-04-01 H Lundbeck As Treatment of cluster headache using anti-CGRP antibodies
US20260001942A1 (en) 2024-06-21 2026-01-01 H. Lundbeck A/S Treatment of headache disorders and/or psychiatric symptoms using anti-cgrp antibodies, and compositions and methods related thereto

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266561A (en) * 1988-01-11 1993-11-30 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
US5364841A (en) * 1988-01-11 1994-11-15 Amylin Pharmaceuticals, Inc. Treatment of obesity and essential hypertension and related disorders

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
GB8720115D0 (en) 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
AU631112B2 (en) * 1988-01-11 1992-11-19 Amylin Corporation Treatment of type 2 diabetes mellitus
US5175145A (en) 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
JPH0666358B2 (ja) * 1989-01-03 1994-08-24 モトローラ・インコーポレーテッド 高密度ソルダ・バンプの製造方法と高密度ソルダ・バンプ用基板ソケット
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
ES2080802T3 (es) * 1989-07-10 1996-02-16 Amylin Pharmaceuticals Inc Uso de un antagonista de amilina en la preparacion de un medicamento para el tratamiento de la obesidad e hipertension intrinseca y desordenes asociados.
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
AU6445894A (en) 1993-03-19 1994-10-11 Duke University Method of treatment of tumors with an antibody binding to tenascin
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
DE69534530T2 (de) 1994-08-12 2006-07-06 Immunomedics, Inc. Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
US6653104B2 (en) 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
EP1461068A4 (en) * 2001-11-26 2006-03-29 Protemix Corp Ltd METHOD AND COMPOSITIONS FOR NORMALIZING LIPID MIRRORS IN MIRACLE TISSUE
CA2541651C (en) 2003-10-22 2011-05-24 Keck Graduate Institute Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
EP3069731A1 (en) * 2005-11-14 2016-09-21 Labrys Biologics Inc. Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
EP2021463B1 (en) 2006-05-19 2016-11-23 Alder Biopharmaceuticals, Inc. Culture method for obtaining a clonal population of antigen-specific b cells
KR20170036814A (ko) 2007-05-21 2017-04-03 앨더바이오 홀딩스 엘엘씨 신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체
TW201531484A (zh) 2007-05-21 2015-08-16 Alder Biopharmaceuticals Inc 抗ＴＮＦ-α之抗體及其用途
DK2164514T3 (en) 2007-05-21 2017-02-27 Alderbio Holdings Llc Antibodies to IL-6 and its use
PE20141787A1 (es) * 2011-05-20 2014-12-07 Alderbio Holdings Llc Composiciones anti-cgrp y uso de las mismas
TWI705825B (zh) * 2011-05-20 2020-10-01 美商艾爾德生物控股有限責任公司 抗降血鈣素基因相關胜肽（ａｎｔｉ－ｃｇｒｐ）或抗降血鈣素基因相關胜肽受器（ａｎｔｉ－ｃｇｒｐ－ｒ）抗體或抗體片段治療或預防慢性及急性型腹瀉之用途
IL243355B2 (en) * 2013-07-03 2024-10-01 Lundbeck Seattle Biopharmaceuticals Inc Regulation of glucose metabolism using anti-cgrp antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266561A (en) * 1988-01-11 1993-11-30 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
US5364841A (en) * 1988-01-11 1994-11-15 Amylin Pharmaceuticals, Inc. Treatment of obesity and essential hypertension and related disorders

Also Published As

Publication number Publication date
KR20160029822A (ko) 2016-03-15
JP6502337B2 (ja) 2019-04-17
CA2916980A1 (en) 2015-01-08
SG10201906172XA (en) 2019-08-27
NZ754427A (en) 2021-12-24
SG11201510618YA (en) 2016-03-30
IL243355B1 (en) 2024-06-01
AU2014285052B2 (en) 2019-09-12
WO2015003122A2 (en) 2015-01-08
EP3016684A2 (en) 2016-05-11
WO2015003122A3 (en) 2015-03-19
JP2018168186A (ja) 2018-11-01
AU2014285052A1 (en) 2016-02-11
ES2911690T3 (es) 2022-05-20
TWI753471B (zh) 2022-01-21
AU2019279945A1 (en) 2020-01-16
CA2916980C (en) 2023-02-21
TWI712419B (zh) 2020-12-11
IL243355A0 (en) 2016-03-31
MX2016000220A (es) 2016-08-18
CN105492026A (zh) 2016-04-13
JP2016528198A (ja) 2016-09-15
KR102476907B1 (ko) 2022-12-13
TW202106335A (zh) 2021-02-16
US20150017166A1 (en) 2015-01-15
NZ715834A (en) 2021-11-26
AU2019279945B2 (en) 2022-01-20
JP2019112455A (ja) 2019-07-11
EP3016684A4 (en) 2017-06-07
EP3016684B1 (en) 2022-02-23
TW201536316A (zh) 2015-10-01
JP2020158525A (ja) 2020-10-01
MX374612B (es) 2025-03-06
IL243355B2 (en) 2024-10-01

Similar Documents

Publication Publication Date Title
CN105492026B (zh) 使用抗cgrp抗体的葡萄糖代谢的调节
US12122821B2 (en) Regulation of glucose metabolism using anti-CGRP antibodies
US11111289B2 (en) Anti-CGRP compositions and use thereof
EP2646468B1 (en) Anti-ngf compositions and use thereof
US10221236B2 (en) Anti-NGF antibodies that selectively inhibit the association of NGF with TRKA without affecting the association of NGF with P75
JP2026016471A (ja) 抗ｃｇｒｐ抗体を用いた頭痛の治療
NZ715834B2 (en) Regulation of glucose metabolism using anti-cgrp antibodies
HK40055862A (en) Anti-cgrp compositions and use thereof
HK40084193A (en) Anti-cgrp compositions and use thereof
HK40009778A (en) Anti-cgrp compositions and use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Washington, DC

Applicant after: Lundbeck Seattle biopharmaceutical Co.

Address before: Washington, DC

Applicant before: ALDER BIOPHARMACEUTICALS, Inc.

CB02 Change of applicant information
TA01 Transfer of patent application right

Effective date of registration: 20210728

Address after: Copenhagen, Denmark

Applicant after: H. LUNDBECK A/S

Address before: Washington, DC

Applicant before: Lundbeck Seattle biopharmaceutical Co.

TA01 Transfer of patent application right
CB02 Change of applicant information

Address after: DanMai Val Be

Applicant after: H. LUNDBECK A/S

Address before: Copenhagen, Denmark

Applicant before: H. LUNDBECK A/S

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant